Inhibition of Factor XIa by Antithrombin I11 by Soons, Hans et al.
 
 
 
Inhibition of Factor XIa by Antithrombin I11
Citation for published version (APA):
Soons, H., Janssen-Claessen, T., Tans, G., & Hemker, H. C. (1987). Inhibition of Factor XIa by
Antithrombin I11. Biochemistry, 26(15), 4624-4629. https://doi.org/10.1021/bi00389a005
Document status and date:
Published: 28/07/1987
DOI:
10.1021/bi00389a005
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Jan. 2021
4624 Biochemistry 1987, 26, 4624-4629 
Lottenberg, R., Hall, J. A., Fenton, J. W., 11, & Jackson, C. 
M. (1982) Thromb. Res. 28, 313-332. 
Lundblad, R. L., Brown, W. V., Mann, K. G., & Roberts, H. 
R. (1980) Chemistry and Biology of Heparin, Elsevier/ 
North-Holland, New York. 
Morrison, J. F. (1982) Trends Biochem. Sci. (Pers. Ed.) 7 ,  
Morrison, J. F., & Stone, S. R. (1985) Comments Mol. Cell. 
Biophys. 2, 347-368. 
Morrison, J. F., & Walsh, C. T. (1987) Adv. Enzymol. Relat. 
Areas Mol. Biol. (in press). 
Okamoto, S., Kinjo, K., Hijikata, A., Kikumoto, R., Tamao, 
Y., Ohkubo, K., & Tonomura, S. (1980) J .  Med. Chem. 
Olson, S. T., & Shore, J. D. (1982) J. Biol. Chem. 257, 
Rosenberg, R. D. (1977) Fed. Proc., Fed. Am. SOC. Exp. Biol. 
102- 105. 
23, 827-830. 
14891-14895. 
36, 10-18. 
Segel, I. H. (1975) Enzyme Kinetics, pp 196-198, Wiley, New 
York. 
Simon, T. L. (1980) in Chemistry and Biology of Heparin 
(Lundblad, R. L., Brown, W. V., Mann, K. G., & Roberts, 
H. R., Eds.) pp 597-61 4, Elsevier/North-Holland, New 
York. 
Sonder, S. A., & Fenton, J. W., I1 (1984) Biochemistry 23, 
Stone, S. R., & Hofsteenge, J. (1986) Biochemistry 25, 
Tollefsen, D. M., Feagler, J. R., & Majerus, P. M. (1974) J .  
Walker, B., Wikstrom, P., & Shaw, E. (1985) Biochem. J. 
Walsmann, P., & Markwardt, F. (1981) Pharmazie 36, 
18 18-1823. 
46 22-46 2 8. 
Biol. Chem. 249, 2646-2651. 
230, 645-650. 
653-660. 
Inhibition of Factor XIa by Antithrombin I11 
Hans Soons,* Truus Janssen-Claessen, Guido Tans, and H. Coenraad Hemker 
Department of Biochemistry, Biomedical Center, University of Limburg, Maastricht, The Netherlands 
Received November 10, 1986; Revised Manuscript Received February 19, 1987 
ABSTRACT: The inactivation of human factor XI, by human antithrombin I11 was studied under pseudo- 
first-order reaction conditions (excess antithrombin 111) both in the absence and in the presence of heparin. 
The time course of inhibition was followed by using polyacrylamide gel electrophoresis in the presence of 
sodium dodecyl sulfate. After electrophoresis, proteins were blotted onto nitrocellulose and stained either 
for glycoprotein or for antithrombin 111 using antibodies against antithrombin 111. Concomitant with factor 
XI, inactivation, two new slower migrating bands, one of which represented the intermediate complex 
consisting of one antithrombin I11 complexed with factor XI,, appeared as a transient band. Complete 
inactivation resulted in a single band representing the complex of factor XI, with two antithrombin I11 
molecules. Quantitative analysis of the time course of inactivation was accomplished by measurement of 
the disappearance of factor XI, amidolytic activity toward the chromogenic substrate S2366. Pseudo- 
first-order reaction kinetics were observed throughout. The rate constant of inactivation was found to  be 
lo3 M-' s-' in the absence of heparin and 26.7 X lo3 M-' s-l in the presence of saturating amounts of heparin. 
From the kinetic data, a binding constant (&) of 0.14 pM was inferred for the binding of antithrombin 
I11 to heparin. The time course of inactivation and the distribution of the reaction products observed upon 
gel electrophoresis a re  best explained assuming a mechanism of inactivation in which the two active sites 
present in factor XI, are inhibited in random order (i.e., independent of each other) with the same rate constant 
of inhibition. 
&'actor XI is a coagulation protein present in plasma in a 
precursor form (Bouma et al., 1977). It is the (pro)enzyme 
that links the contact phase to the intrinsic factor IX activation. 
Four proteins appear to be involved in contact activation re- 
actions: factor XII, factor XI, prekallikrein, and high mo- 
lecular kininogen (Cochrane & Griffin, 1982). Active factor 
XI1 with high molecular weight kininogen as a cofactor can 
convert factor XI to an active form (Griffin & Cochrane, 
1979), which subsequently is able to activate factor IX by 
hydrolyzing two internal peptide bonds (Di Scipio et al., 1978). 
Factor XI is a dimeric molecule which contains two identical 
protein chains (80 000 molecular weight) held together by (a) 
disulfide bond(s). Factor XI is converted to factor XI, by the 
cleavage of an internal peptide bond in both precursor chains. 
Factor XI, is composed of two heavy chains ( M ,  50 000) and 
two light chains ( M ,  33 000) and contains one active site a t  
each light chain (Bouma et al., 1977; Fujikawa et al., 1986). 
* Address correspondence to this author 
It is the only known enzyme participating in blood coagulation 
that contains two active sites. 
Four plasma protease inhibitors, a,-antitrypsin, anti- 
thrombin 111, c, inhibitor, and a2-antiplasmin, have been 
reported to inactivate human factor XI,. In plasma, cy1- 
antitrypsin is thought to be the main factor XI, inhibitor 
followed by antithrombin 111 (Scott et al., 1982a). However, 
the inactivation by antithrombin 111 can be accelerated in the 
presence of heparin (Damus et al., 1973). Scott et al. reported 
a 4-fold enhancement while Beeler et al. reported a 40-fold 
acceleration of the inactivation at saturating heparin con- 
centrations (Scott et al., 1982b; Beeler et al., 1986). 
The stoichiometry of the complex formed between factor 
XI, and antithrombin 111 has been shown to be 1 mol of factor 
XI, to 2 mol of inhibitor (Kurachi & Davie, 1977), indicating 
that both active sites interact with antithrombin 111. Thus, 
the presence of an intermediate, factor XI, complexed with 
one antithrombin 111, formed during the inactivation of factor 
XI, is likely to be expected but has not been demonstrated yet. 
0006-2960/87/0426-4624$01.50/0 0 1987 American Chemical Society 
I N H I B I T I O N  O F  F A C T O R  X I ,  
The kinetics of the inactivation of both active sites of factor 
XI, as well as the mutual interactions of factor XI,, anti- 
thrombin 111, and heparin remain also to be established. 
This study was undertaken to explore the kinetics of the 
inactivation of factor XI, by antithrombin I11 in the presence 
and absence of heparin. A model is suggested in which the 
two active sites of factor XI, are inhibited independent of each 
other by antithrombin I11 and in which the enhancement of 
the inactivation due to the presence of heparin is correlated 
to the binding of antithrombin 111 to heparin. 
MATERIALS AND METHODS 
Materials. Chromogenic substrates pyro-Glu-Pro-Arg-p- 
nitroanilide (pNA) (S2366) and H-D-Pro-Phe- Arg-pNA 
(S2302) were purchased from AB Kabi Diagnostica, Sweden. 
Rabbit anti-human antithrombin 111, concanavalin A, and 
horseradish peroxidase were obtained from Sigma Chemical 
Co., St. Louis, MO. Nitrocellulose membrane was from 
Bio-Rad Laboratories, Richmond, CA. 3,3'-Diaminobenzidine 
tetrahydrochloride was purchased from Fluka AG, Switzer- 
land. Swine anti-rabbit IgG horseradish peroxidase conjugated 
antibodies were obtained from Nordic, Tilburg, Holland. All 
reagents used were of the highest grade commercially available. 
Proteins. Human factor XI was purified according to 
Bouma et al. (1983). Human factor XI1 was isolated as 
described by Griffin and Cochrane (1976). Human anti- 
thrombin I11 was purified as described by Thaler and Schmer 
(1975). @-Factor XII, was prepared from purified factor XI1 
as described by Fujikawa and McMullen (1983). Human 
serum albumin (Sigma) was further purified on a concanavalin 
A-Sepharose column to remove glycoprotein impurities. 
Factor XI, factor XII, and antithrombin I11 preparations were 
homogeneous and pure as determined by gel electrophoresis 
in the presence of sodium dodecyl sulfate on 10% gels ac- 
cording to Laemmli (1 970). The specific activities determined 
in a clotting assay for factors XI and XI1 were 21 1 and 74 
units/mg, respectively, assuming 1 unit to be present per 
milliliter of normal human plasma. All proteins were stored 
at  -70 OC after dialysis against 50 mM tris(hydroxy- 
methy1)aminomethane hydrochloride (Tris-HC1)/ 175 mM 
NaC1, pH 7.9, for human antithrombin I11 and 4 mM sodium 
acetate, 2 mM acetic acid, 0.15 M NaCl, and 0.5 mM eth- 
ylenediaminetetraacetic acid (EDTA), pH 5 .O, for human 
factors XI and XII. 
Heparin was crude porcine intestinal mucosal heparin 
(Organon). It had a mean molecular weight of 15000 and 
an anti-X, and anti-thrombin activity of 175 units/mg. 
Preparation of human factor XI ,  from human factor XI 
using human @-factor XII, was performed as described earlier 
(Soons et al., 1986). Factor XI, was separated from @-factor 
XII, on a DEAE-Sephadex column (1.5 X 11.5 cm) at 4 'C 
in 50 mM Tris-HC1 and 150 mM NaCl at pH 8.0. 
Amidolytic activity of human factor XI, was measured by 
using the chromogenic substrate S2366 in a buffer containing 
50 mM Tris-HC1, 175 mM NaC1, 20 mM EDTA, and 0.5 
mg/mL human serum albumin, pH 7.9. The kinetic param- 
eters of the hydrolysis of the chromogenic substrate S2366 by 
hcman factor XI, were K ,  = 0.42 mM and k,,, = 758 s-l. 
Protein concentrations were routinely determined according 
to Bradford (1976). Factor XI, concentrations were expressed 
as 80000 molecular weight subunits (van der Graaf et al., 
1983). Antithrombin I11 concentration was measured by 
employing an E280nm (1%) of 5.7 (Kurachi & Davie, 1977) and 
by a titration against a known concentration human thrombin. 
Gel Electrophoretic Analysis. Proteins were subjected to 
gel electrophoresis in the presence of sodium dodecyl sulfate 
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on 5% slab gels as described by Laemmli (1970) and subse- 
quently transferred onto nitrocellulose sheets as described by 
Towbin et al. (1979). The blots were soaked in 0.1% bovine 
serum albumin and 0.05% Tween-20 in phosphate-buffered 
saline. Immunological detection of antithrombin 111 and an- 
tithrombin 111-protease complexes was performed essentially 
as described by Towbin et al. (1979) with rabbit anti-human 
antithrombin I11 and using swine anti-rabbit IgG conjugated 
with horseradish peroxidase as second antibodies. Glycoprotein 
staining was performed as described by Clegg (1982) by in- 
cubating the blots with concanavalin A (50 pg/mL) in 
phosphate-buffered saline containing 1 mM CaCl,, 0.1 mM 
MgC12, 0.1 mM MnC12, 0.1% bovine serum albumin, and 
0.05% Tween-20. Horseradish peroxidase (10 pg/mL) in the 
same buffer was used as indicator. Staining of the blots was 
achieved by soaking in a freshly prepared and filtered solution 
of diaminobenzidine tetrahydrochloride (0.5 mg/mL) and 
0.01% H 2 0 2  in 0.05 M Tris-HC1, pH 7.5. 
Fluorescence studies were performed with an SLM/Aminco 
SPF-500 C spectrophotometer at 25 "C. The excitation and 
emission wavelengths were 285 and 345 nm (band-passes of 
2 and 5 nm, respectively). The interaction of heparin with 
antithrombin I11 was measured by changes in the intrinsic 
fluorescence of antithrombin 111. Small aliquots of heparin 
were added in succession to a solution of antithrombin I11 (1 
and 2 pM) in 50 mM Tris-HCl/lOO mM NaCl, pH 7.5. After 
each addition, the intrinsic fluorescence intensity of anti- 
thrombin I11 was determined. The data were plotted, and the 
titer was measured from the point of intersection of lines drawn 
through the ascending limbs and the plateaus of the plots. 
Kinetic Data Analysis. The disappearance of factor XI, 
amidolytic activity appeared to follow pseudo-first-order re- 
action kinetics both in the absence and in the presence of 
heparin over the whole time course of inactivation. Since 
inactivation was only complete upon covalent binding of two 
antithrombin I11 molecules to each factor XI, dimer, it appears 
that the reaction of a catalytic site of factor XI, occurs in a 
random fashion and is not influenced by the fact of whether 
or not the other active site in the dimer has already been 
occupied by another antithrombin I11 (AT-111) molecule (also 
see Results). Therefore, the inactivation can be described as 
(1) 
in which XI, is the concentration of factor XI, expressed per 
M, 80000 subunit. The rate constant k, can then be obtained 
as described in the legend to Figure 1. 
The stimulation of the inhibition of factor XI, by anti- 
thrombin 111 due to the presence of heparin was assumed to 
be due to the binding of antithrombin 111 to heparin. In that 
case, the reaction is given as 
ki 
XI, + AT-111 + XI,*AT-I11 
k i  
XI, + AT-111,- XI,.AT-111 
k2 
XI, + AT-IIIb - XI,.AT-111 
in which XI, is again the concentration of factor XI, expressed 
per M ,  80 000 subunit and in which AT-111, and AT-IIIb are 
the concentrations of free antithrombin 111 and of antithrombin 
I11 bound to heparin, respectively. k ,  and k2 are the rate 
constants of inactivation by free antithrombin 111 and by the 
antithrombin 111-heparin complex. Assuming rapid binding 
equilibrium, the rate equation can be written as 
d[XI,] /dt = -(kl [AT-IIIf] + k2[AT-IIIb]) [XIa] (111) 
and the slope of a pseudo-first-order plot will equal - ( k l -  
[AT-III,] + k2[AT-IIIb]). k, and k2 can be independently 
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heparin concentrations. At a given heparin concentration. the 
rate of factor XI, inhibition was determined at varying an- 
tithrombin 111 concentrations. At each concentration of an- 
tithrombin 111, the amounts of antithrombin 111 bound and 
free were calculated from the slope of the pseudo-first-order 
plot of inactivation using the experimentally determined kt 
and k2 as described above. The binding constant Kd is given 
as 
Kd = [AT-IIIr][Sr]/[AT-~~rbj (W 
and this can be rearranged to 
Thus, the binding constant Kd and the total amount of binding 
sites present (&) at the given heparin concentration can be 
determined from a plot of l/[AT-IIIb] vs. l/[AT-IlI~]. 
RESULTS 
The inhibition of human factor XI. by human antithrombin 
111 was studied in the present and absence of heparin by 
measurement of the disappearance of factor XI, amidolytic 
activity toward the chromogenic substrate S2366. The reaction 
was pseudo first order in factor XI, since a semilogarithmic 
plot of the residual amidolytic activity vs. time yielded a 
straight line (Figure IA).  The apparent first-order rate 
constant obtained from the slope of these lines was directly 
proportional to the amount of antithrombin 111 present (Figure 
IB). Therefore, in aggreement with the literature (Scott et 
al., 1982.a). the inactivation was found to be second order, and 
the rate constant obtained was IO' M-l s-l. Figure 2A shows 
that in the presence of heparin (0.1 mg/mL) the reaction was 
also pseudo first order but the rate of inactivation was in- 
creased some 30-fold. At saturating amounts of heparin (sa 
also below), the mnd-order  rate constant of inactivation was 
It has been shown that factor XI. consists of two identical 
subunits of 80000 each which both contain an active site. The 
stoichiometry of the interaction of factor XI. with antithrombin 
111 has been shown to be 1:2 (Kurachi & Davie. 1977). in- 
dicating that both active sites bocome occupied. However, to 
our knowledge, the intermediate in which one active site is 
l / [AT-1bI  = (Kd/~ ,~) ( l / [AT- l I I r l )  + 1/Sm (V) 
26.7 x 103 M-' S-1. 
l".cli".lion tim. t mi" I AT 111 t p U  1 
FIGURE I: Inactivation of human factor XI. by human antithrombin 
111 in the absence of heparin. Factor XI, was incubated at 37 OC 
in 50 mM Tris (pH 7.5 at 37 "C). 175 mM NaCI. 20 mM EDTA, 
and 0.5 mg/mL human serum albumin. After 5 min. reaction was 
started by adding varying amounts of antithrombin Il l .  Final con- 
mtrations were 8 nM factor XI. and antithrombin 111 in micromolar 
as indicated in the figure. (Panel A) At the time points indicated, 
aliquots were removed from the reaction mixture and diluted 20-fold 
in the above-mentioned buffer containing 0.29 mM S2366. The 
amidolytic activity remaining was determined by measurement of the 
rate of change in absorbance at 405-500 nm on an Aminco DW2a 
spectrophotometer set in the dual-wavelength mode. The residual 
amidolytic activity was expressed as the percentage of the original 
amidolytic activity present in the absence of antithrombin 111 taken 
as 103%. Panel B shows the pseudo-first-order rate constant obtained 
from the slopes of the plots shown in panel A as a function of the 
concentration of antithrombin 111 present. 
determined. Measurement of the reaction in the absence of 
heparin (all antithrombin 111 is free) yields k ,  and in the 
presence of saturating amounts of heparin (all antithrombin 
111 is bound) yields kl. Thus, from the observed rates of factor 
XI. inactivation, the binding of antithrombin 111 to heparin 
can be determined. It should be stressed that in the above 
equation it is tacitly assumed that the binding equilibrium of 
antithrombin 111 binding to heparin is not influenced by factor 
XI. or by the prcduced factor XI*-antithrombin 111 complexes. 
Since the reaction kinetics appear to remain first order in factor 
XI. over a wide range of factor XI. concentrations (0.1-200 
nM), this assumption appears to hold. 
Binding of Antithrombin III to Heparin. The binding pa- 
rameters (Kd and amount of binding sites) of antithrombin 
111 binding to heparin were determined from the kinetic data 
of factor XI, inactivation a t  varying antithrombin 111 and 
- -- \ 
x) m Jo C255.=?152 b6D15'lOJoU C.?.55~?l524S~?52Q3045 
TIME (mkl nyE (nn) TIME (nkl 
~ G U R E  2 Inactivation of human factor XI, by human antithrombin 111 in the presence of heparin. Factor XI, (8 nM) and heparin (0.1 mg/mL) 
were preincubatcd at 37 OC in 50 mM T i s  (pH 7.5 at 37 "C), 175 mM NaCI. 20 mM EDTA, and 0.5 mg/mL human serum albumin. After 
5 min. reaction was started with the addition of antithrombin 111 to result in a final concentration of 64 nM. At the time points indicated 
in the figure. aliquots were withdrawn from the reaction mixture for the determination of the amidolytic activity remaining (panel A)  and 
for gel electrophoresis under nonreducing conditions on 5% slab gels (panels B and C). (Panel A) From the residual amidolytic activity present 
in the sample, the pseudo-first-order plot was constructed as described in the legend to Figure 1. The obtained pseudo-first-order reaction 
rale constant was 0.13 min-I. (Panel B) After gel electrophoresis, protein was blotted onto nitrocellulose sheets and stained for glycoprotein 
using concanavalin A. (Panel C) A second blot was stained for antithrombin 111 antigen using antibodies against human antithrombin 111. 
For further experimental details. see Materials and Methods. 
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occupied has never been shown, and no attempts have been 
made yet to correlate the occurrence of the various reaction 
products with the disappearance of factor XI, amidolytic 
activity. Therefore, during the time course of factor XI, 
inactivation, samples were withdrawn from the reaction 
mixture and subjected to sodium dodecyl sulfate (SDS)-5% 
polyacrylamide gel electrophoresis under nonreducing con- 
ditions. The protein bands were blotted onto nitrocellulose 
sheets and subsequently stained for glycoprotein using con- 
canavalin A (Figure 2B). Since factor XI, and antithrombin 
I11 are glycoproteins, both were stained by using this method. 
Factor XI, was present as a single band, and antithrombin I11 
migrated at the dye front of the gel (lane C, Figure 2B). Free 
antithrombin I11 was not visible on the blots because it mi- 
grates at the dye front together with an excess of carrier protein 
(human serum albumin) that interferes with the staining of 
the free antithrombin 111. The glycoprotein pattern on the 
blot showed three protein bands, which changed in intensity 
during the inactivation of factor XI,. The protein band, 
representing factor XI,, decreased in intensity during the in- 
activation, and after 10 min, no factor XI, was visible. 
Concomitantly, two slower migrating bands appeared. Both 
these bands stained positive for antithrombin I11 antigen using 
rabbit anti-human antithrombin I11 antibodies (Figure 2C). 
Free factor XI, was not visible on this blot. These results 
demonstrate the appearance and disappearance of the inter- 
mediate (in which only one active site is occupied in factor 
XI,) during the time course of the reaction. This intermediate, 
which represents the faster migrating band, rapidly appeared 
and reached an optimum between 2 and 15 min after which 
it slowly decreased. The slowest migrating band, representing 
the final reaction product (one factor XI, and two anti- 
thrombin I11 molecules), gradually increased during the time 
course of factor XI, inactivation. From the data represented 
in Figure 2A-C, it is clear that only the final reaction product 
had no amidolytic activity. However, although factor XI, 
rapidly disappeared within 10 min and substantial amounts 
of intermediate were visible on the gels, the reaction remained 
first order throughout the whole time course of inactivation 
(Figure 2A). This strongly suggests that both active sites in 
factor XI, are inactivated with the same rate constant inde- 
pendent of each other (Le., irrespective of whether or not the 
other site is already occupied). In such a model, the distri- 
bution of the various reaction products (i.e., XI,, XI,-AT-111, 
and XIa.2AT-III) at each given time interval can be calculated 
by using the rate constant determined from the pseudo- 
first-order plot (see also legend to Figure 3). Figure 3 shows 
the result of such a calculation for the experiment described 
in Figure 2. As can be seen, the appearance and disappearance 
of the various reaction products as calculated correlate quite 
well with the distribution of these products as seen on the blots 
in Figure 2. 
The inactivation of factor XI, by antithrombin I11 in the 
presence of heparin is a three-component reaction. To in- 
vestigate the mutual interactions, the concentration of each 
of the three components was varied while the two others were 
kept constant. Figure 4A shows that the pseudo-first-order 
reaction rate constant increased, when factor XI, (8 nM) and 
antithrombin I11 (0.1 pM) were titrated with heparin 
(0.067-10 pM) and reached a plateau at  a heparin concen- 
tration of approximately 5 pM. The second-order reaction 
rate constant a t  saturating heparin concentrations was cal- 
culated to be 26.7 X lo3 M-' s-l. Figure 4B shows that the 
pseudo-first-order reaction rate constant also increased, when 
at  a constant concentration of factor XI, (8 nM) and heparin 
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FIGURE 3: Calculated time course of appearance and disappearance 
of reaction products during the inactivation of factor XI, by anti- 
thrombin I11 in the presence of heparin. The time course of the changes 
in the concentration of factor XI, (-), factor XI, complexed with 
one antithrombin 111 (-e-), and the final reaction product, factor XI, 
complexed with two antithrombin 111 molecules (--), was calculated 
for the experiment presented in Figure 2. For the calculation, it was 
assumed that (1) both active sites had the same amidolytic activity, 
(2) both active sites were independent of each other inhibited by 
antithrombin I11 with the same measured pseudo-first-order reaction 
rate constant ( k ) ,  and (3) the factor XI, dimer disappeared with a 
rate constant of 2k. With these assumptions, the amount of factor 
XI, decreased in time according to Ce-*kt while factor XI, complexed 
with one or two antithrombin 111's increased in time according to 
The constant C was the amount of factor XI, present at the beginning 
and was taken as 100% and k was 0.13 min-' as obtained from the 
2C(@ - e -2kf ) and C(l - 2e-kf + e-2kf), respectively (Moore, 1972). 
data 
1 
C 
'E - 
X 
of Figure 2. 
AT Ill ( p M )  Heparin ( p M  
FIGURE 4: Titration experiments. Panel A shows the changes in the 
pseudo-first-order reaction rate constant, k ,  when factor XI, (8 nM) 
and antithrombin I11 (100 nM) were titrated with heparin (range: 
0.067-10 pM). The pseudo-first-order reaction rate constants were 
obtained as described in the legend to Figure 1, and at least seven 
time points were used. Panel B shows the changes in the pseudo- 
first-order reaction rate constant, k ,  when factor XI, (8 nM) and 
heparin (0.3 fiM) were titrated with antithrombin 111 (range: 0.05-1.0 
pM) (closed circles). This experiment was also performed in the 
absence of heparin (closed triangles). 
(0.3 pM) the concentration of antithrombin I11 was increased 
(0.05-1.0 pM). The rate constant did not reach a plateau 
(closed circles). This is due to the fact that the rate constant 
of factor XI, inhibition in the absence of heparin (closed 
triangles) was not negligible. The pseudo-first-order reaction 
rate constant did not change (k = 0.15 min-') when heparin 
(0.17 pM) and antithrombin I11 (1 .O pM) were titrated with 
factor XI, (0.1-200 nM). These data suggest that the rate 
of inactivation of factor XI, by antithrombin I11 in the presence 
of heparin is a direct measure for the binding of antithrombin 
I11 to heparin and that this binding is not influenced by factor 
XI,. That this is indeed the case is illustrated in Figure 5 in 
which the data of the experiment presented in Figure 4 were 
used to obtain the binding data of antithrombin I11 to heparin. 
For this, the data were analyzed as described under Materials 
4628 B I 0 (.: II E M I S 'r R Y 
-.TI---- .-.. '/ a -
q 
\ 
r- 
-. - ----...--A- ----".A 
20  40 
l / A T I I I  f r e e . 1 0 - ~  (M-') 
FIGURE 5 :  Replot of the data of Figure 4B according to the model 
presented in eq 11. For each total antithrombin I11 concentration, 
the concentrations of bound and free antithrombin 111 were calculated 
as described under Materials and Methods, and their reciprocals were 
plotted against each other. The binding parameters of the antithrombin 
111-heparin interaction were a Kd of 142 nM and 0 42 antithrombin 
111 binding site per mole of heparin according to eq V 
and Methods using rate constants of I O 3  M s I for the in- 
hibition of factor XI, by free antithrombin I11 and of 26.7 X 
lo3 M-' s for heparin-bound antithrombin 111. Figure 5 
shows a plot calculated from the data shown in Figure 4B. As 
can be seen, a straight line was obtained from which a Kd of 
142 nM was determined. The amount of sites present on 
heparin was calculated to be 0.42 mol of antithrombin Ill per 
mole of heparin assuming a molecular weight of 1 5  000 for 
the heparin. 
DISCUSSION 
T'he results presented in this paper give insight in the way 
via which the two active sites in factor XI, are inhibited by 
antithrombin JIJ. In aggreement with earlier studies (Kurachi 
& Davie. 1977; Scott et al., 1982a), it was found that the final 
reaction product has no amidolytic activity and consists of a 
complex of factor XI, to which two antithrombin IT1 molecules 
become attached. However, the experiments presented in 
Figure 2 also clearly demonstrate the occurrence of the in- 
termediate consisting of one factor XI, with one antithrombin 
111 molecule as a transient product during the time course of 
the reaction. To our knowledge, this is the first time that this 
intermediate has been unequivocally demonstrated using gel 
electrophoretic techniques. The intermediate appears ami- 
dolytically active since even when the band representing free 
factor XI, has disappeared there is still considerable amidolytic 
activity present in the reaction mixture. However, in ag- 
greenient with the literature (Scott et al., 1982b), it was found 
that both in the absence and in the presence of heparin the 
disappearance of factor XI, amidolytic activity cannot be 
distinguished from pseudo-first-order kinetics over the whole 
time course of the reaction. This is most likely explained by 
a mechanism in which both active sites of factor XI, interact 
with antithrombin 111 in random order (Le., independent of 
each other) with the same rate constant. The changes in the 
distribution of the reaction products visible on the gels during 
the time course of the reaction correlate well with changes 
calculated according to such a model (cf. Figures 2 and 3) .  
Simulation experiments showed that, as soon as the two rate 
constants would differ by a factor of 2 or more, a deviation 
of pseudo-first-order kinetics would have been readily ob- 
servable (data not shown). 
The kinetic data  obtained i n  the presence of heparin can 
be used to determine the binding parameters of antithrombin 
111 binding to heparin (cf. Figures 4 and 5). The Kd of 142 
nM determined is in good agreement with that reported in the 
literature (Griffith, 1982). The stoichiometry of the interaction 
of antithrombin IJI with heparin was found to be 0.42 mol of 
antithrombin III/mol of heparin assuming an average mo- 
lecular weight of 15 000 for the heparin used. This is some- 
what lower than reported in the literature (Nesheim et al., 
1986). The stoichiometry of the interaction was confirmed 
for the used reactants by independent measurement using the 
fluorescence technique described by Nesheim et al. (1986) 
(data not shown). Therefore, it seems justified to conclude 
that the stimulation of the reaction by heparin is due to the 
binding of antithrombin 111 to heparin and since the inacti- 
vation remains first order for all the concentrations of factor 
XIa tested (0.1 -200 nM) the binding of antithrombin IJI to 
heparin is apparently not influenced by factor XI, and/or by 
the reaction products formed. It has been shown that factor 
X1, binds to heparin Sepharose (ersterud & Rapaport, 1977). 
Therefore, it can be expected that factor XI, may interact with 
heparin under our experimental conditions. At the moment, 
we do not know whether binding of factor XI, to heparin 
influences the rate of factor XI, inactivation by antithrombin 
111. If such is the case, however, the fact that the reaction 
is saturable with heparin and the fact that the kinetics are first 
order in factor XIa, indicate then either that all factor XI, has 
to be bound or that no factor XI, is bound a t  all to heparin 
under our conditions. 
s in  the ab- 
sence of heparin and 26 7 X 10' M s [ in the presence of 
saturating amounts of hepar in J his rate enhancement induced 
by heparin is in good aggreenient with the value reported by 
Beeler et ai. (1986). However, the actual values of rate 
constants reported here are considerably higher than earlier 
reported values (Beeler et al., 1986: Scott et al , 1982b). Apart 
fiorn differelices in experimental conditions, a possible ex- 
planation for these discrepancies is that in  the present study 
factor XI actitated by P.factor X11, was used whereas in the 
previous studies trypsin-activated factor XI  has been used. 
Similar difference? have been reported for the enzymatic ac- 
tivity of factor XI, in the activation of factor I X  (Walsh et 
a]., 1984; Soons et al., 1986). Reeler et 211. have argued that 
under certain conditions antithrombin JIl may become a 
physiologically significant inhibitor of factor XI, (Reeler et 
al., 1986). 'J he finding that the rates of inactivation of @-factor 
XII, activated factor X I  are even higher thari the values re. 
ported by these authors can be regarded to support this con- 
cept It should be stressed, however, that the conditions i n  
whole plasma are so much more complicated than those in 
purified systems that rnuch inore will need to be done to gain 
insight in  the biologicill importaticr of the regulation of factor 
X1, inactivation by antithrornbin JTI. 
Finally. we would like to emphasire that our data pertain 
to the niechanisrn of  the interaction of the two active sites 111 
factor XI, with its macromolecular substrate antithrombin JII. 
The intriguing question remains whether the remaining active 
site in a factor XI, molecule, complexed with one antithrombin 
111, can dsv interact with factor 1X the same way as free factor 
XI, or vrhether in this case changes occur in the mechanism 
of activation of factor 1X by factor XI,. 
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Acceptor-Donor Relationships in the Transglutaminase-Mediated Cross-Linking of 
Lens @-Crystallin Subunits? 
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ABSTRACT: Following the isolation of the Nf-(y-glutamy1)lysine-containing polymers from human cataracts, 
our efforts were directed to induce such cross-links experimentally in rabbit lens, and evidence was obtained 
for the selective reactivities of certain @-crystallin subunits in this transglutaminase-catalyzed event. In 
the present work, we examined the enzymatic cross-linking of purified crystallins individually (a ,  PH, PL, 
and y) and in combinations, with particular emphasis on forming the approximately 55K dimer. This species 
was the primary product in the cross-linking of PH-crystallins; PL also reacted with transglutaminase. Neither 
a- nor y-crystallins formed appreciable amounts of cross-linked structures with transglutaminase. Dan- 
sylcadaverine, known to compete against the reactive lysines of proteins in forming Ne-(y-glutamy1)lysine 
cross-bridges, was shown to inhibit the generation of dimeric and higher ordered oligomers from PH and 
PL. The fluorescent amine specifically labeled only two subunits in PH (-29-30K and -26K) and one 
in PL (- 26K), identifying these substrates as possessing transglutaminase-reactive endo-y-glutaminyl residues. 
An antiserum to bovine PBp recognized the -23K subunit of rabbit P-crystallins and also the -55K dimer, 
suggesting that the -23K protein participates as a lysine donor in generating the cross-linked dimer with 
transglutaminase. Inasmuch as the same antiserum reacts with a -5OK material reported to appear in 
increasing amounts with age in human lens, the results lend added support to the physiological significance 
of transglutaminase in the aging of lens. 
Isolating N'-(y-glutamyl)lysine peptides from polymers which 
are characteristically present only in cataractous specimens 
called attention to the role of transglutaminase in lens (Lorand 
et al., 1981). Previous work focused on reactions catalyzed 
by the intrinsic enzyme, activated from its latent form by 
adding Ca2+ to homogenates of rabbit lens or to the whole 
organ. Using the enzyme-directed incorporation of amines 
'This work was aided by USPHS Research Career Award HL-03512 
and by Grant EY-03942 from the National Institutes of Health. 
( [14C]putrescine or N-(5-aminopentyl)-5-(dimethylamino)- 1 - 
naphthalenesulfonamide (dansylcadaverine)) as a strategy for 
identifying acceptor proteins [see Lorand and Conrad (1984)], 
it could be shown that, among all the crystallin components 
Abbreviations: SDS, sodium dodecyl sulfate; EDTA, ethylenedi- 
aminetetraacetate; DTT, dithiothreitol; PAGE, polyacrylamide gel 
electrophoresis; Mr, relative molecular weight; K, X 10': dansylcadaverine, 
N-(5-aminopentyl)-S-(dimethylamino)- 1 -naphthalenesulfonamide; Tris- 
HCI, tris(hydroxymethy1)aminomethane hydrochloride. 
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